William D. Figg

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 979 citations

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

Austin G. Duffy, Susanna V. Ulahannan, Oxana Makorova-Rusher et al. · Journal of Hepatology · 2016 · 800 citations · Full text

Hepatology, Medicine, Pathology +6

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Richard Piekarz, Robin Frye, Maria L. Turner et al. · Journal of Clinical Oncology · 2009 · 728 citations · Full text

Immunology, Pathology, Pharmacotherapy +18

Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

Kevin C. Conlon, Enrico Lugli, Hugh C. Welles et al. · Journal of Clinical Oncology · 2014 · 686 citations · Full text

Selumetinib in Children with Inoperable Plexiform Neurofibromas

Andrea M. Gross, Pamela L. Wolters, Eva Dombi et al. · New England Journal of Medicine · 2020 · 647 citations · Full text